Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project

Julie K K Vishram; Anders Borglykke; Anne H Andreasen; Jørgen Jeppesen; Hans Ibsen; Torben Jørgensen; Luigi Palmieri; Simona Giampaoli; Chiara Donfrancesco; Frank Kee; Giuseppe Mancia; Giancarlo Cesana; Kari Kuulasmaa; Veikko Salomaa; Susana Sans; Jean Ferrieres; Jean Dallongeville; Stefan Söderberg; Dominique Arveiler; Aline Wagner; Hugh Tunstall-Pedoe; Wojciech Drygas; Michael H Olsen; on behalf of the MORGAM Project

doi:10.1371/journal.pone.0107294

Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project

Julie K K Vishram, Anders Borglykke, Anne H Andreasen, Jørgen Jeppesen, Hans Ibsen, Torben Jørgensen, Luigi Palmieri, Simona Giampaoli, Chiara Donfrancesco, Frank Kee, Giuseppe Mancia, Giancarlo Cesana, Kari Kuulasmaa, Veikko Salomaa, Susana Sans, Jean Ferrieres, Jean Dallongeville, Stefan Söderberg, Dominique Arveiler, Aline WagnerHugh Tunstall-Pedoe, Wojciech Drygas, Michael H Olsen, on behalf of the MORGAM Project

Medicinsk Afdeling GLO

119 Citationer (Scopus)

Abstract

OBJECTIVE: To investigate the influence of age and gender on the prevalence and cardiovascular disease (CVD) risk in Europeans presenting with the Metabolic Syndrome (MetS).

METHODS: Using 36 cohorts from the MORGAM-Project with baseline between 1982-1997, 69094 men and women aged 19-78 years, without known CVD, were included. During 12.2 years of follow-up, 3.7%/2.1% of men/women died due to CVD. The corresponding percentages for fatal and nonfatal coronary heart disease (CHD) and stroke were 8.3/3.8 and 3.1/2.5.

RESULTS: The prevalence of MetS, according to modified definitions of the International Diabetes Federation (IDF) and the revised National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII), increased across age groups for both genders (P<0.0001); with a 5-fold increase in women from ages 19-39 years to 60-78 years (7.4%/7.6% to 35.4%/37.6% for IDF/NCEP-ATPIII) and a 2-fold increase in men (5.3%/10.5% to 11.5%/21.8%). Using multivariate-adjusted Cox regressions, the associations between MetS and all three CVD events were significant (P<0.0001). For IDF/NCEP-ATPIII in men and women, hazard ratio (HR) for CHD was 1.60/1.62 and 1.93/2.03, for CVD mortality 1.73/1.65 and 1.77/2.06, and for stroke 1.51/1.53 and 1.58/1.77. Whereas in men the HRs for CVD events were independent of age (MetS*age, P>0.05), in women the HRs for CHD declined with age (HRs 3.23/3.98 to 1.55/1.56; MetS*age, P = 0.01/P = 0.001 for IDF/NCEP-ATPIII) while the HRs for stroke tended to increase (HRs 1.31/1.25 to 1.55/1.83; MetS*age, P>0.05).

CONCLUSION: In Europeans, both age and gender influenced the prevalence of MetS and its prognostic significance. The present results emphasise the importance of being critical of MetS in its current form as a marker of CVD especially in women, and advocate for a redefinition of MetS taking into account age especially in women.

Originalsprog	Engelsk
Tidsskrift	P L o S One
Vol/bind	9
Udgave nummer	9
Sider (fra-til)	e107294
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0107294
Status	Udgivet - 2014

Adgang til dokumentet

10.1371/journal.pone.0107294

Citationsformater

Vishram, J. K. K., Borglykke, A., Andreasen, A. H., Jeppesen, J., Ibsen, H., Jørgensen, T., Palmieri, L., Giampaoli, S., Donfrancesco, C., Kee, F., Mancia, G., Cesana, G., Kuulasmaa, K., Salomaa, V., Sans, S., Ferrieres, J., Dallongeville, J., Söderberg, S., Arveiler, D., ... on behalf of the MORGAM Project (2014). Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project. P L o S One, 9(9), e107294. https://doi.org/10.1371/journal.pone.0107294

Vishram, JKK, Borglykke, A, Andreasen, AH, Jeppesen, J, Ibsen, H, Jørgensen, T, Palmieri, L, Giampaoli, S, Donfrancesco, C, Kee, F, Mancia, G, Cesana, G, Kuulasmaa, K, Salomaa, V, Sans, S, Ferrieres, J, Dallongeville, J, Söderberg, S, Arveiler, D, Wagner, A, Tunstall-Pedoe, H, Drygas, W, Olsen, MH & on behalf of the MORGAM Project 2014, 'Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project', P L o S One, bind 9, nr. 9, s. e107294. https://doi.org/10.1371/journal.pone.0107294

@article{719fce5eb4544f848fc4f9313d62929c,

title = "Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project",

abstract = "OBJECTIVE: To investigate the influence of age and gender on the prevalence and cardiovascular disease (CVD) risk in Europeans presenting with the Metabolic Syndrome (MetS).METHODS: Using 36 cohorts from the MORGAM-Project with baseline between 1982-1997, 69094 men and women aged 19-78 years, without known CVD, were included. During 12.2 years of follow-up, 3.7%/2.1% of men/women died due to CVD. The corresponding percentages for fatal and nonfatal coronary heart disease (CHD) and stroke were 8.3/3.8 and 3.1/2.5.RESULTS: The prevalence of MetS, according to modified definitions of the International Diabetes Federation (IDF) and the revised National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII), increased across age groups for both genders (P<0.0001); with a 5-fold increase in women from ages 19-39 years to 60-78 years (7.4%/7.6% to 35.4%/37.6% for IDF/NCEP-ATPIII) and a 2-fold increase in men (5.3%/10.5% to 11.5%/21.8%). Using multivariate-adjusted Cox regressions, the associations between MetS and all three CVD events were significant (P<0.0001). For IDF/NCEP-ATPIII in men and women, hazard ratio (HR) for CHD was 1.60/1.62 and 1.93/2.03, for CVD mortality 1.73/1.65 and 1.77/2.06, and for stroke 1.51/1.53 and 1.58/1.77. Whereas in men the HRs for CVD events were independent of age (MetS*age, P>0.05), in women the HRs for CHD declined with age (HRs 3.23/3.98 to 1.55/1.56; MetS*age, P = 0.01/P = 0.001 for IDF/NCEP-ATPIII) while the HRs for stroke tended to increase (HRs 1.31/1.25 to 1.55/1.83; MetS*age, P>0.05).CONCLUSION: In Europeans, both age and gender influenced the prevalence of MetS and its prognostic significance. The present results emphasise the importance of being critical of MetS in its current form as a marker of CVD especially in women, and advocate for a redefinition of MetS taking into account age especially in women.",

author = "Vishram, {Julie K K} and Anders Borglykke and Andreasen, {Anne H} and J{\o}rgen Jeppesen and Hans Ibsen and Torben J{\o}rgensen and Luigi Palmieri and Simona Giampaoli and Chiara Donfrancesco and Frank Kee and Giuseppe Mancia and Giancarlo Cesana and Kari Kuulasmaa and Veikko Salomaa and Susana Sans and Jean Ferrieres and Jean Dallongeville and Stefan S{\"o}derberg and Dominique Arveiler and Aline Wagner and Hugh Tunstall-Pedoe and Wojciech Drygas and Olsen, {Michael H} and {on behalf of the MORGAM Project}",

year = "2014",

doi = "10.1371/journal.pone.0107294",

language = "English",

volume = "9",

pages = "e107294",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "9",

}

TY - JOUR

T1 - Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project

AU - Vishram, Julie K K

AU - Borglykke, Anders

AU - Andreasen, Anne H

AU - Jeppesen, Jørgen

AU - Ibsen, Hans

AU - Jørgensen, Torben

AU - Palmieri, Luigi

AU - Giampaoli, Simona

AU - Donfrancesco, Chiara

AU - Kee, Frank

AU - Mancia, Giuseppe

AU - Cesana, Giancarlo

AU - Kuulasmaa, Kari

AU - Salomaa, Veikko

AU - Sans, Susana

AU - Ferrieres, Jean

AU - Dallongeville, Jean

AU - Söderberg, Stefan

AU - Arveiler, Dominique

AU - Wagner, Aline

AU - Tunstall-Pedoe, Hugh

AU - Drygas, Wojciech

AU - Olsen, Michael H

AU - on behalf of the MORGAM Project

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: To investigate the influence of age and gender on the prevalence and cardiovascular disease (CVD) risk in Europeans presenting with the Metabolic Syndrome (MetS).METHODS: Using 36 cohorts from the MORGAM-Project with baseline between 1982-1997, 69094 men and women aged 19-78 years, without known CVD, were included. During 12.2 years of follow-up, 3.7%/2.1% of men/women died due to CVD. The corresponding percentages for fatal and nonfatal coronary heart disease (CHD) and stroke were 8.3/3.8 and 3.1/2.5.RESULTS: The prevalence of MetS, according to modified definitions of the International Diabetes Federation (IDF) and the revised National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII), increased across age groups for both genders (P<0.0001); with a 5-fold increase in women from ages 19-39 years to 60-78 years (7.4%/7.6% to 35.4%/37.6% for IDF/NCEP-ATPIII) and a 2-fold increase in men (5.3%/10.5% to 11.5%/21.8%). Using multivariate-adjusted Cox regressions, the associations between MetS and all three CVD events were significant (P<0.0001). For IDF/NCEP-ATPIII in men and women, hazard ratio (HR) for CHD was 1.60/1.62 and 1.93/2.03, for CVD mortality 1.73/1.65 and 1.77/2.06, and for stroke 1.51/1.53 and 1.58/1.77. Whereas in men the HRs for CVD events were independent of age (MetS*age, P>0.05), in women the HRs for CHD declined with age (HRs 3.23/3.98 to 1.55/1.56; MetS*age, P = 0.01/P = 0.001 for IDF/NCEP-ATPIII) while the HRs for stroke tended to increase (HRs 1.31/1.25 to 1.55/1.83; MetS*age, P>0.05).CONCLUSION: In Europeans, both age and gender influenced the prevalence of MetS and its prognostic significance. The present results emphasise the importance of being critical of MetS in its current form as a marker of CVD especially in women, and advocate for a redefinition of MetS taking into account age especially in women.

AB - OBJECTIVE: To investigate the influence of age and gender on the prevalence and cardiovascular disease (CVD) risk in Europeans presenting with the Metabolic Syndrome (MetS).METHODS: Using 36 cohorts from the MORGAM-Project with baseline between 1982-1997, 69094 men and women aged 19-78 years, without known CVD, were included. During 12.2 years of follow-up, 3.7%/2.1% of men/women died due to CVD. The corresponding percentages for fatal and nonfatal coronary heart disease (CHD) and stroke were 8.3/3.8 and 3.1/2.5.RESULTS: The prevalence of MetS, according to modified definitions of the International Diabetes Federation (IDF) and the revised National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII), increased across age groups for both genders (P<0.0001); with a 5-fold increase in women from ages 19-39 years to 60-78 years (7.4%/7.6% to 35.4%/37.6% for IDF/NCEP-ATPIII) and a 2-fold increase in men (5.3%/10.5% to 11.5%/21.8%). Using multivariate-adjusted Cox regressions, the associations between MetS and all three CVD events were significant (P<0.0001). For IDF/NCEP-ATPIII in men and women, hazard ratio (HR) for CHD was 1.60/1.62 and 1.93/2.03, for CVD mortality 1.73/1.65 and 1.77/2.06, and for stroke 1.51/1.53 and 1.58/1.77. Whereas in men the HRs for CVD events were independent of age (MetS*age, P>0.05), in women the HRs for CHD declined with age (HRs 3.23/3.98 to 1.55/1.56; MetS*age, P = 0.01/P = 0.001 for IDF/NCEP-ATPIII) while the HRs for stroke tended to increase (HRs 1.31/1.25 to 1.55/1.83; MetS*age, P>0.05).CONCLUSION: In Europeans, both age and gender influenced the prevalence of MetS and its prognostic significance. The present results emphasise the importance of being critical of MetS in its current form as a marker of CVD especially in women, and advocate for a redefinition of MetS taking into account age especially in women.

U2 - 10.1371/journal.pone.0107294

DO - 10.1371/journal.pone.0107294

M3 - Journal article

C2 - 25244618

SN - 1932-6203

VL - 9

SP - e107294

JO - P L o S One

JF - P L o S One

IS - 9

ER -

Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater